$ARM — This week’s research cycle was dominated by AI-driven infrastructure and software calls, blockbuster pharma momentum, and pervasive valuation debates—many high‑quality franchises trading near analyst targets. Our digest summarizes 140+ pieces, synthesizes cross-cutting patterns, highlights contrarian opportunities (photonics, quantum, advanced nuclear), and sets a focused research agenda for the coming week.